Singularity Therapeutics

Singularity Therapeutics is a pre-clinical stage biotechnology company focused on developing novel therapies for autoimmune and inflammatory diseases. The company's research is centered on the selective inhibition of the Toll-like receptor 7 (TLR7) pathway, which plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE). Its lead candidate, ST-301, is a potent and highly selective small molecule TLR7 inhibitor that has demonstrated robust efficacy in delaying the onset and progression of lupus nephritis in murine models. Singularity Therapeutics operates in close association with the Hillhouse Medical Group to advance its pipeline of immunology-focused therapeutics.